Molecular characterization of metastatic colorectal cancer (mCRC) in patients (pts) treated with cetuximab and pembrolizumab.

被引：0
|
作者：
Fountzilas, Christos
Rosario, Spencer
Withers, Henry G.
Mukherjee, Sarbajit
Bajor, David L.
Saltzman, Joel N.
Wang, Chong
Attwood, Kristopher
Knudsen, Erik S.
Witkiewicz, Agnieszka K.
Iyer, Renuka V.
Boland, Patrick M.
机构：
[1] Roswell Pk Comprehens Canc Ctr, Div GI Med, Dept Med, Buffalo, NY USA
[2] Roswell Pk Comprehens Canc Ctr, Buffalo, NY USA
[3] Case Western Reserve Univ, Case Comprehens Canc Ctr, Univ Hosp, Seidman Canc Ctr, Cleveland, OH USA
[4] Cleveland Clin, Cleveland, OH USA
[5] Rutgers Canc Inst New Jersey, New Brunswick, NJ USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
178
引用
收藏
页码：178 / 178
页数：1
相关论文
共 50 条
  • [21] An international consortium study in chemorefractory metastatic colorectal cancer (mCRC) patients (pts) to assess the impact of FCGR polymorphisms on cetuximab efficacy.
    Geva, R.
    Jensen, B. V.
    Fountzilas, G.
    Yoshino, T.
    Paez, D.
    Montagut, C.
    Sougklakos, I.
    Cappuzzo, F.
    Cervantes-Ruiperez, A.
    Papamichael, D.
    Frattini, M.
    Vincenzi, B.
    Macarulla, T.
    Loupakis, F.
    Spindler, K. G.
    Qvortrup, C.
    Ciardiello, F.
    Tejpar, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [22] Cetuximab and capecitabine as first-line treatment for elderly patients (pts) with metastatic colorectal cancer (mCRC): Preliminary results of TTD trial
    Gravalos, C.
    Rivera, F.
    Massuti, B.
    Sastre, J.
    Marcuello, E.
    Valladares, M.
    Gil, S.
    Abad, A.
    Diaz-Rubio, E.
    Aranda, E.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [23] Successful desensitization with cetuximab (CET) after hypersensitivity reaction (HSR) to panitumumab (PAN) and CET in patients (pts) with metastatic colorectal cancer (mCRC)
    Shah, M. M.
    Hotchkiss, S.
    Shanley, J.
    Davies, M. J.
    Ferencz, T. M.
    Syrigos, K. I.
    Syrigos, K.
    Saif, M. W.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [24] Results of a german noninterventional study (NIS) of cetuximab-based therapy in pretreated-patients (pts) with metastatic colorectal cancer (mCRC).
    Jehn, C.
    Stenzel, K.
    Boening, L.
    Kroening, H.
    Possinger, K.
    Lueftner, D.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [25] CIRCULATING AMPHIREGULIN (AR) PLASMA LEVELS AS SURROGATE PHARMACODYNAMIC MARKERS OF EGFR INHIBITION WITH CETUXIMAB IN METASTATIC COLORECTAL CANCER (MCRC) PATIENTS (PTS)
    Cremolini, C.
    Loupakis, F.
    Fioravanti, A.
    Lupi, C.
    Orlandi, P.
    Salvatore, L.
    Fontanini, G.
    Danesi, R.
    Bocci, G.
    Falcone, A.
    ANNALS OF ONCOLOGY, 2010, 21 : 68 - 68
  • [26] Analysis of potential predictive factors of clinical benefit in patients (pts) with metastatic colorectal cancer (MCRC) treated with single-agent cetuximab as first-line treatment
    Gravalos, C.
    Sastre, J.
    Aranda, E.
    Massuti, B.
    Vega-Villegas, M. E.
    Gomez, A.
    Varella-Garcia, M.
    Jimeno, A.
    Diaz-Rubio, E.
    Hidalgo, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [27] Cetuximab plus irinotecan in patients (pts) with metastatic colorectal cancer (mCRC) failing prior oxaliplatin-based therapy: the EPIC trial
    Scheithauer, W.
    Sobrero, A.
    Lenz, H. J.
    Maurel, J.
    Lutz, M.
    Middleton, G.
    Saleh, M.
    Zubel, A.
    Williams, K.
    Burris, H. A., III
    EJC SUPPLEMENTS, 2007, 5 (04): : 235 - 236
  • [28] Cetuximab given every 2 weeks (q2w) plus irinotecan, as feasible option, for previously treated patients (pts) with metastatic colorectal cancer (MCRC)
    Roca, J.
    Alonso, V.
    Pericay, C.
    Escudero, P.
    Grande, C.
    Vicente, P.
    Arrivi, A.
    Martin, C.
    Moreno, I.
    Garcia, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [29] Assessing QoL in patients with metastatic colorectal cancer (mCRC) treated with chemotherapy
    Miller, KL
    Johnson, LL
    Colwell, HH
    Bhattacharyya, SK
    Deeter, RG
    Mathias, SD
    VALUE IN HEALTH, 2005, 8 (06) : A49 - A49
  • [30] Phase Ib study of drozitumab combined with cetuximab (CET) plus irinotecan (IRI) or with FOLFIRI ± bevacizumab (BV) in previously treated patients (Pts) with metastatic colorectal cancer (mCRC)
    Baron, A. D.
    O'Bryant, C. L.
    Choi, Y.
    Ashkenazi, A.
    Royer-Joo, S.
    Portera, C. C.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
12345